ClinicalTrials.gov
public full text
Public Domain
Oxcarbazepine Plus Morphine in Patients With Refractory Cancer Pain
This is an open-label, single arm, Phase Ib dose escalation study of Oxcarbazepine with morphine in patients with refractory cancer pain. The primary endpoint is to evaluate the safety and toxicity of the combination of Oxcarbazepine plus morphine. The secondary endpoints are improving pain control, reduce morphine use and improve the quality of life.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Comparison of Morphine and Morphine Plus Dexmedetomidine in Chronic Cancer Pain#848273
- An Interventional Study for Patient With Cancer Pain to Evaluate the Efficacy and Safety of OxyNorm® Compared to Morphine Sulfate Through the IV Continuous Infusion.#875351
- Morphine as First Drug for Cancer Pain#1096368
- Buprenorphine vs. Opioid Dose Escalation Among Patients With Chronic Pain#1170960
- Effect of Electroacupuncture on Opioid-induced Constipation in Patients With Cancer#1164975
Record · ID 1161374
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive